Abstract

In the era of big data, young patients are overwhelmed by artificial intelligence-based tools, such as chatbots. Five clinical experts were asked to evaluate the performance of four of the most currently used chatbots at providing information on a rare cancer affecting young people, such as rhabdomyosarcoma. In general, despite their high performance at giving general information about the disease, these chatbots were considered by the experts inappropriate at providing suggestion on cancer treatments and specialized centers, also lacking of "sensitivity". Efforts are envisioned by the pediatric oncology community to improve the quality of data used to train these tools.